Back to CYTKView full pipeline
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
View Full LandscapeDrug Information
Target Indication
Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
Clinical Trial
NCT06793371Last updated: 10/20/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
Omecamtiv Mecarbil (OM)Phase 3
Heart Failure
AficamtenPhase 3
Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Omecamtiv MecarbilPhase 3
Heart Failure With Reduced Ejection Fraction
Aficamten (CK-3773274)Phase 3
Obstructive Hypertrophic Cardiomyopathy (oHCM)
tirasemtivPhase 3
Amyotrophic Lateral Sclerosis (ALS)
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts